NIPH Clinical Trials Search

UMIN ID: C000000293

Registered date:31/05/2008

Outcome Assessment using SF-36 v2 in Stroke Patient Study

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedBrain infarction
Date of first enrollment2005/10/01
Target sample size2400
Countries of recruitmentJapan
Study typeObservational


Primary OutcomeTo determine the SF-36 v2 score and to investigate the effect on QOL of vertigo, dizziness, presyncope, and light-headedness after chronic brain infarction
Secondary Outcome

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1. Patients who cannot read, understand and fill in the questionnaire by themselves 2. Patients who idle their time away 3. Patients who are hospitalized 4. Patients who are undergoing treatment for dizziness, vertigo, presyncope, light-headedness which are likely due to chronic cerebral circulation impairment associated with sequelae of brain infarction 5. Patients whose dizziness, vertigo, presyncope, and light-headedness is definitely or likely caused by Meniere disease, vestibular neuronitis, benign paroxysmal positional vertigo, otitis media, or epilepsy 6. Patients whom the investigator judges are not suitable to participate in the study

Related Information


public contact
Name Takashi Shimokoube
Address 5, Kanda Surugadai 2-Chome, Chiyoda-Ku, Tokyo 101-8311, Japan Japan
Telephone 03-3293-3422
Affiliation Kyorin Pharmaceutical Co., Ltd P.L.C. Management Department
scientific contact
Name Yukito Shinohara
Address Nishiki Cho, 4-2-22, Tachikawa City, Tokyo, Japan, 151-0053 Japan
Telephone 042-523-3131
Affiliation KYOSAI Tachikawa HOSPITAL Neurology